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Purine-converting enzymesPurinergic signaling cascade includes the release of endogenous ATP and other agonists by chemical and me-
chanical stimuli, modulation of diverse cellular functions and subsequent ectoenzymatic inactivation. Basal
release of extracellular purines and its physiological relevance remain controversial. Here we employed a
combination of enzyme-coupled approaches for simultaneous bioluminescent (ATP, ADP, PPi) and ﬂuoromet-
ric (AMP, adenosine, inosine, hypoxanthine) measurements of ATP and its metabolites without additional
manipulations or derivatization of sampled biological ﬂuids. By using these sensing techniques, extracellular
purines were determined in various cells and tissues both at resting and pro-inﬂammatory conditions. The
results obtained revealed the ability of endothelial, lymphoid and tumor cells to maintain extracellular
ATP, ADP and adenosine at certain characteristic nanomolar levels. By quantifying the amounts of endoge-
nously released and/or exogenously applied purines and their metabolites, these sensing techniques may
be applied for evaluating purine-converting pathways on the cell surfaces and also for ex vivo analysis of pu-
rine homeostasis in the intact tissues. Furthermore, we provide novel insight into the mechanisms underlying
tumorigenic effects of ATP by demonstrating the ability of metastatic prostate carcinoma PC3 and breast can-
cer MDA-MB-231 cells to maintain PPi, which derives from extracellular ATP in the course of nucleotide
pyrophosphatase/phosphodiesterase reaction. Collectively, the results imply a complex pattern of nucleotide
turnover where extracellular ATP, ADP and adenosine are maintained at steady-state levels via
counterbalanced release and inactivation of ATP and other purines, and further suggest the importance of
basal agonist release for continuous activation and/or desensitization of purinergic receptors.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Extracellular purines are important signaling molecules regulat-
ing diverse responses in cardiovascular, nervous and other systems
[1–3]. Purinergic signaling is thought to represent a multistep coor-
dinated cascade, including stimulated release of endogenous ATP
and ADP, triggering of signaling events via a series of ligand-gated
P2X and G-protein coupled P2Y receptors and further nucleotide
breakdown to adenosine. Cellular mechanisms underlying nucleo-
tide release substantially vary depending on the cell type and stimuli
applied and may particularly include cargo-vesicle trafﬁcking andnosine 5′-phosphosulfate; BSS,
scular endothelial cells; HRP,
endothelial cells; KRPG, Krebs
oinosine; NDPK, nucleoside di-
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ne nucleoside phosphorylase;
oratory, University of Turku,
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rights reserved.exocytotic granule secretion via vesicular nucleotide transporters;
electrodiffusional movement through ATP-conducting anion channels
or connexin/pannexins hemichannels; and facilitated diffusion by
nucleotide-speciﬁc transporters of the ABC protein family [4–7]. Subse-
quent to the signal transduction, extracellular ATP and other nucleo-
tides need to be rapidly inactivated to adenosine. General schemes of
nucleotide hydrolysis have included a role for the enzymes of
ecto-nucleoside triphosphate diphosphohydrolase (NTPDase) family,
ecto-nucleotide pyrophosphatase/phosphodiesterase (NPP) family,
ecto-5′-nucleotidase/CD73 and alkaline phosphatases [4,8,9]. The
resulting adenosine in turn binds to its own nucleoside-selective
G-protein coupled receptors [1,2] and ﬁnally, is inactivated on the
cell surface [4] and/or uptaken by the cell via nucleoside transporters
[10].
Recent advances in our understanding of the “release-signaling-
inactivation” sequence provide signiﬁcant justiﬁcation for re-examination
of the current models of purinergic machinery. Firstly, along with the
common viewof extracellular ATP as a ligand for P2 receptors, substrate
for ecto-nucleotidases and source of adenosine, this nucleotide was
shown to concurrently serve as a phosphoryl donor for counteracting
ecto-adenylate kinase and nucleoside diphosphate kinase (NDPK)
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inactivating and transphosphorylating, pathways represents a princi-
pally distinct route for appearance and tuned regulation of purinergic
agonist levels on the cell surface. Secondly, along with transient release
of nucleotides by various excitatory/secretory and non-excitatory tis-
sues and cells under different mechanical, chemical and other stimuli,
some cells constitutively release ATP at certain basal rates [5,14]. Con-
tinuous presence of extracellular ATP may have physiological implica-
tions for diverse cell responses, including regulation of blood ﬂow,
control of cell growth, neuronal activity, and response to pathogens
[5]. Thirdly, innovative ATP-sensing assays provide independent lines
of evidence that micromolar levels of ATP can be spatially conﬁned
in the pericellular space of lymphocytes [15], astrocytoma cells [16],
platelets [17], epithelial cells [14,18], tumor cells [19] and other cell
types [4,20], with only minor nucleotide portion being diffused and/
or convected into the bulk medium. Fourthly, by using microelectrode
biosensors, it was shown that other purinesmay appear in the extracellu-
larmilieu in response to hypoxia and ischemia viadirect release of endog-
enous adenosine from hippocampal slices [21,22] as well as inosine and
hypoxanthine from cerebellar cultures and slices [23]. Lastly, the impor-
tance of yet another product of extracellular ATP metabolism, pyrophos-
phate (PPi), has been emerged recently, which particularly contributes
to the regulation of bone and cartilage mineralization [24], calciﬁcation
of rat vascular smoothmuscle cells [25,26] and inhibition of caspase-1 ac-
tivation and interleukin-1β release in the course of macrophage differen-
tiation into anti-inﬂammatory phenotype [27].
Despite the signiﬁcant progress in our understanding of extracel-
lular signaling pathways, there is still a need for simple and reliable
assays for detecting nanomolar levels of purinergic agonists and
their metabolites in extracellular ﬂuids. This study was undertaken
(a) to elaborate a combination of enzyme-coupled bioluminescent
and ﬂuorometric assays appropriate for simultaneous measurement
of the whole spectrum of adenine nucleotides, nucleosides and their
metabolites in nanomolar range; and (b) by using these sensing tech-
niques, to evaluate extracellular purine homeostasis in various cells
and tissues during short-term (≤3 h) incubations under deﬁned in
vitro conditions. The results obtained revealed the ability of endothe-
lial, lymphoid and tumor cells to maintain extracellular ATP, ADP and
adenosine, as well as PPi (in case of metastatic tumor cell lines) at cer-
tain characteristic nanomolar levels and further suggest the impor-
tance of these basal agonist levels for continuous activation and/or
desensitization of purinergic receptors.
2. Materials and methods
2.1. Cell cultures
Human umbilical vein endothelial cells (HUVEC) were isolated
from fresh umbilical cords of 8–10 different donors by treatment
with collagenase, as described elsewhere [28]. HUVEC were cultured
in endothelial cell growth medium EGM-2 BulletKit (Lonza,
Walkersville, MD, USA) and were used in the experiments between
passages 3 and 5. Human dermal microvascular endothelial cells
(HDMEC) from three different donors were purchased from
PromoCell GmbH (Heidelberg, Germany) and cultured in the accom-
panying endothelial cell growth medium MV with Supplement Mix.
EAhy926 cell line (derived by the fusion of HUVEC with the continu-
ous human lung carcinoma cell line A549), human leukemic T-cell
lymphoblast line Jurkat (clone E6-1), prostate carcinoma cell line
PC3, breast cancer cell line MDA-MB-231, and mouse B16-F10 mela-
noma cells were from ATCC (Manassas, USA). PC3 cells were
maintained in Gibco Ham's F-12K medium containing 10% fetal calf
serum. Other cells were cultured either in RPMI-1640 (Jurkat and
EAhy926) or Dulbecco's Modiﬁed Eagle's (MDA-MB-231 and
B16-F10) medium supplemented with 10% fetal calf serum, 4 mM
L-glutamine, 1 mM sodium pyruvate, 100 U/ml penicillin and 100 μg/mlstreptomycin. Endothelial and tumor cells were maintained at 37 °C in a
humidiﬁed atmosphere of 5% CO2 and seeded onto 24-well tissue culture
plate in complete media at a density ~50,000 cells/well for 24–48 h to
reach the conﬂuence.
2.2. Cell treatments
2.2.1. Study 1
For measurement of extracellular ATP, ADP and adenosine, mono-
layers of adherent cells or suspensions of Jurkat T-lymphocytes
(2×105 cells/well) were washed and equilibrated at 37 °C in
24-well plate in the starting volume of 1 ml Krebs Ringer phosphate
glucose (KRPG; comprising: 145 mM NaCl, 5.7 mM sodium phos-
phate, 4.86 mM KCl, 0.54 mM CaCl2, 1.22 mM MgSO4, and 5.5 mM
glucose; pH 7.35). Aliquots of the bathing medium (260 μl) were
carefully collected from the top of the wells at different intervals, ei-
ther from non-stimulated cells or after cell stimulation with different
drugs and heat-inactivated (5 min at 60 °C). The following drugs
were dissolved from stock solutions and applied onto the cells at
1:100–1:500 dilutions: pro-inﬂammatory cytokine human recombi-
nant tumor necrosis factor-α (TNFα, 200 U/ml) and interleukin 1β
(500 U/ml) (R&D Systems), endotoxin lipopolysaccharide from
Escherichia coli O111:B4 (LPS, 10 ng/ml), non-hydrolysable cAMP an-
alogue dibutyryl cAMP (20 μg/ml), as well as inhibitor of nucleoside
transport S-(4-nitrobenzyl)-6-thioinosine (NBT, 1 μM) (all from
Sigma). Each drug was tested prior to the experimentation to ensure
that it does not interfere with the employed luminometric and ﬂuoro-
metric assays. There was also no change in cell viability with any of
these maneuvers.
2.2.2. Study 2
In the second study, cultured cells were incubated at 37 °C in
24-well plate in 1 ml of basal salt solution (BSS; comprising: 130 mM
NaCl, 5 mM KCl, 1.5 mM CaCl2, 1 mM MgSO4, 25 mM HEPES, 5 mM
glucose and 0.1% bovine serum albumin; pH 7.4) in the absence and
presence of exogenous ATP or adenosine (2 μM). After 1‐hour incuba-
tion, 700 μl of bathing medium was collected, heat-inactivated and
assayed for ATP, ADP, AMP, adenosine, inosine, hypoxanthine and PPi
levels, as speciﬁed below.
2.3. Enzyme-coupled assay for ﬂuorometric detection of AMP, adenosine,
inosine and hypoxanthine
A novel sensing technique has been elaborated using speciﬁc mix-
ture of enzymes sequentially converting purines into uric acid and
H2O2, followed by ﬂuorometric detection of the generated H2O2
(Fig. 1). Basic principle of the employment of enzyme-coupled reac-
tions for determination of the purine bases had been proposed over
50 years ago [29] and since then the technique has been further de-
veloped and adapted for electrochemical detection of adenosine and
inosine by using microelectrode biosensors [21,30,31]. Here, we
employed a highly sensitive and stable probe 10-acetyl-3,7-
dihydroxyphenoxazine (Amplex Red reagent) which reacts with
H2O2 in the presence of horseradish peroxidase (HRP) with a 1:1 stoi-
chiometry to produce ﬂuorescent resoruﬁn. Aliquots of conditioned
medium (40–60 μl) were transferred into separate wells in white
96-well microplates containing various combinations of the following
enzymes in a ﬁnal volume of 170 μl appropriate buffer (either KRPG
or BSS): 0.15 U/ml 5′-nucleotidase from Crotalus adamanteus
venom, 0.3 U/ml adenosine deaminase (ADA, type IX from calf
spleen), 0.25 U/ml bacterial purine nucleoside phosphorylase (PNP)
and 0.15 U/ml microbial xanthine oxidase (XO; all from Sigma).
After 20 min incubation at RT, 30 μl of H2O2-detecting mixture
containing HRP (ﬁnal concentration 1 U/ml, Sigma) and Amplex Red
reagent (60 μM, Invitrogen, Molecular Probes) was added to the
microwells, followed by measurement of the ﬂuorescence intensity
Fig. 1. Development of enzyme-coupled ﬂuorometric purine-sensing assay. Addition of certain purine to the indicated mixtures of soluble enzymes caused its sequential conversion
from AMP via adenosine (Ado), inosine (Ino) and hypoxanthine (Hyp) into uric acid and H2O2, with the latter metabolite being recorded ﬂuorometrically using HRP and Amplex Red
reagent. Differential recordings between wells “A and B”, “B and C”, “C and D”, and “D and E” yield signals that are linearly related to the concentrations of AMP, adenosine, inosine
and hypoxanthine, respectively. Calibration curves were generated for each experiment using identical coupled reactions with serial dilutions of AMP, adenosine, inosine, hypoxan-
thine and H2O2 standards, as well as the ultimate product of this catalytic chain, resoruﬁn (Resor, Invitrogen, Molecular Probes).
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spectively (Tecan Inﬁnite M200, Salzburg, Austria). Particularly, the
ﬁrst well contained the complete enzymatic cascade (“mix A”),
while in the parallel well the ﬂuorescence was recorded using the
same mixture but without 5′-nucleotidase (mix “B”) (Fig. 1). A differ-
ential recording between wells “A” and “B” yields signals that are lin-
early related to the concentrations of AMP. For adenosine sensing, the
background ﬂuorescence determined in the absence of ADA (mix “C”)
has been subtracted from the ﬂuorescence in well “B” containing the
complete adenosine-converting cascade. Likewise, differential re-
cordings between wells “C” and “D” and between “D” and “E” yield
signals that are linearly related to the concentrations of inosine and
hypoxanthine, respectively (Fig. 1).Fig. 2. Bioluminescent assays for quantiﬁcation of ATP, ADP and PPi. (A) Luciferin/luciferase
assay was devised for simultaneous determination of ATP and ADP, with the latter nucleo-
tide being detected by converting ADP into ATP in the presence of exogenous UTP and
NDPK. (B) PPi reacts with exogenous APS in the presence of ATP-sulfurylase to generate
ATP, which can be measured then by a coupled luciferin/luciferase reaction. Calibration
curveswere generated for each experiment using identical coupled reactionswith serial di-
lutions of ATP, ADP (A) and PPi (B) standards, as illustrated on the right panels. Ordinates
show arbitrary units of luminescence (AUL, ×103).2.4. Bioluminescent assays for quantiﬁcation of ATP, ADP and PPi in
extracellular medium
For sensing ADP we took advantage of enzyme-coupled assay [32].
The principle of the assay is based on rapid ADP transphosphorylation
with excessive amount of exogenous UTP in the presence of
NDPK, with the generated product ATP being detected by a coupled
luciferin/luciferase reaction (Fig. 2A). Speciﬁcally, 60-μl aliquots of
conditioned medium were transferred into two wells of white non-
phosphorescent 96-well microplate containing 90 μl distilled water
without (A) or with (B) a mixture of UTP and NDPK from baker's
yeast Saccharomyces cerevisiae (ﬁnal concentrations 20 μM and
0.6 U/ml, respectively; Sigma) and incubated for 15 min. Subsequent
to addition of 50 μl ATP-monitoring reagent (ATPLite assay kit, Perkin
Elmer, Groningen, TheNetherlands), luminescence of the sampleswas
measured using a microplate reader (Tecan Inﬁnite M200). Notewor-
thy, the measured luminescence in well “B” basically represents the
integral value for ATP+ADP concentrations. Therefore, ATP was
recorded in the parallel well “A” without UTP/NDPK reaction mixture
and this value was subtracted from the above bioluminescence to
yield speciﬁc ADP-dependent bioluminescence.To quantify extracellular PPi we adapted an enzyme-linked biolumi-
nescent assay originally developed for monitoring inorganic pyrophos-
phate synthesis in chromatophores [33] and more recently modiﬁed
Fig. 3. Maintenance of basal extracellular purine concentrations by various cells. Cul-
tures of Jurkat T-lymphocytes, HUVEC, HDMEC, EAhy926 (Eahy), MDA-MB-231
(MDA), PC3, and B16-F10 (B16) cells were incubated at 37 °C in 24-well-plate. Aliquots
of the medium were collected after 60 (open bars) and 180 (closed bars) min and
assayed for ATP (A), ADP (B) and adenosine (C) concentrations. The results are
presented as mean±SEM for at least 5 independent experiments performed in dupli-
cate wells. Panel D represents the ratio of average extracellular ATP and adenosine con-
centrations shown in panels A and C, respectively.
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this assay system, PPi reacts with adenosine 5′-phosphosulfate (APS) in
the presence of ATP sulfurylase to generate ATP which is measured by a
coupled luciferin/luciferase reaction (Fig. 2B). Here, we modiﬁed and
combined this bioluminescent approach with the above ATP/
ADP-sensing technique, thus allowing us to detect nanomolar concen-
trations of ATP, ADP and PPi within the same sample. Brieﬂy, the ali-
quots of the medium (60 μl) were transferred into parallel Eppendorf
tubes and mixed with 20 μl of BSS alone (“A”) or supplemented with
mixtures of UTP and NDPK (ﬁnal concentrations 20 μM and 0.6 U/ml)
(“B”) or APS and ATP sulfurylase (20 μM and 0.01 U/ml; all from
Sigma) (“C”). Samples were incubated either for 15 min at RT (tubes
A and B) or 40 min at 37 °C (tube C) and then heat-inactivated. 70-μl
aliquots of the mixture were transferred into white 96-well plate
followed by addition of 10 μl 5× concentrated ATP-monitoring reagent
and measurement of luminescence by Tecan Inﬁnite M200. The differ-
ences in luminescence signals between wells “C” (ATP+PPi) and “A”
(only ATP) allowed quantifying the concentration of PPi, which was
converted into ATP through the ATP-sulfurylase reaction in the pres-
ence of APS. Likewise, the signal in well “A” was subtracted from the
value in well “B” to yield speciﬁc ADP-speciﬁc bioluminescence. The
linearity of the reaction as a function of ATP, ADP and PPi concentra-
tions is illustrated in Fig. 2.
2.5. Thin-layer chromatographic (TLC) analysis of purine-converting
pathways
Cultured adherent cells or Jurkat T-lymphocyte suspensions
(2×105 cells/well) were incubated at 37 °C in 24-well plate in the
starting volume of 250 μl BSS containing 4 mM β-glycerophosphate
and 10 μM ATP with tracer [2,8-3H]ATP (Perkin Elmer) or 10 μM
[2-3H]adenosine (Amersham Biosciences) as initial substrates.
Aliquots of the mixture (8 μl, ~5×104 dpm/spot) were periodically
applied to an Alugram SIL G/UV254 TLC sheets (Macherey-Nagel,
Duren, Germany). 3H-labeled nucleotides and nucleosides were sepa-
rated by using appropriate solvent systems and quantiﬁed by scintilla-
tion β-counting, as described earlier [34]. For autoradiographic
analysis of [γ-32P]ATP metabolism, PC3 and MDA-MB-231 cells were
seeded overnight in 96-well ﬂat bottom clear plates at a density
10,000 cells/well. Nucleotidemetabolismwas evaluated by incubating
the adherent cells for 20 min at 37 °C in a ﬁnal volume of 80 μl
Dulbecco's Modiﬁed Eagle's medium containing 10 μM [γ-32P]ATP
(Perkin Elmer), 4 mM β-glycerophosphate and various unlabeled
nucleotides. Aliquots of the mixture were spotted onto Polygram
CEL-300 PEI sheets (Macherey-Nagel), separated by TLC with 0.75 M
KH2PO4 (pH 3.5) as solvent and developed by autoradiography.
2.6. Ex vivo analysis of extracellular purines and PPi in human umbilical
cords
Fresh human umbilical cords (8-cm length) were sequentially
washed with 10 ml of Hank's Buffered Salt Solution and twice with
BSS. After infusion of 2 ml of BSS medium, the cords were clamped
at both ends and incubated on a water bath for 20 min at 37 °C. The
conditioned medium was collected by syringe, heat-inactivated
(5 min at 60 °C) and assayed for purine nucleotides, nucleosides
and PPi as speciﬁed above. The same procedure was repeated by addi-
tional incubation of umbilical cords for 20 min with 2 ml BSS
supplemented with 2 μM ATP or adenosine.
2.7. Statistical analysis
Each treatment was performed in duplicate or triplicate wells and
data are expressed as mean±SEM from at least three independent
experiments.3. Results
3.1. Cells maintain extracellular ATP, ADP and adenosine at certain char-
acteristic nanomolar levels both at resting and pro-inﬂammatory
conditions
Fig. 3 summarizes the measurements obtained with conditioned
medium from various non-stimulated cells. ATP and ADP concentra-
tions in the low nanomolar range (~2–5 nM) were detected in the
wells with cultured HUVEC, HDMEC and EAhy926 cells. By contrast,
tumor cells PC3, MDA-MB-231, B16-F10 and especially Jurkat
T-lymphocytes maintained relatively high (up to 25 nM) nucleotide
levels after 1-hour incubation, which slightly tended to decay after
3-hour equilibration. Concurrent measurement of adenosine also
revealed extracellular concentrations of this nucleoside within
30–90 nM range (Fig. 3C). Surprisingly, except for ecto-5′-
nucleotidase/CD73-negative Jurkat T-cells containing 16±5 nM
(n=4) AMP, extracellular levels of this purine in other cells studied
1971M. Helenius et al. / Biochimica et Biophysica Acta 1823 (2012) 1967–1975were below the threshold detection limit of this assay (~5 nM or
1 pmol/well). Given that ATP and adenosine mediate diverse and
often opposite responses [2,7], evaluation of the relationship between
these key signaling molecules might provide additional information
about the predominance of metabolic pathways for particular cell
type. Interestingly, in comparison with Jurkat T-cells, HUVEC and
HDMEC are characterized by relatively low ATP/adenosine ratio
(Fig. 3D).
By having veriﬁed that cultured cells maintain extracellular pu-
rines at certain characteristic baseline levels, we then questioned
whether various stimuli can trigger additional release of endogenous
purines. Challenging of cultured HUVEC, EAhy926 and Jurkat T-cells
for 1 h with pro-inﬂammatory agents TNFα, interleukin-1β and
dibutyryl cAMP did not affect ATP and adenosine levels (Fig. 4), and
similar results were obtained after 3-hour incubation (data not
shown). In the presence of pro-inﬂammatory endotoxin LPS, extracel-
lular concentrations of adenosine, but not ATP, were increased by
~50%. Treatment of HUVEC with inhibitor of nucleoside transport
NBT was accompanied by 2-fold increase of adenosine (Fig. 4B).
These ﬁndings are consistent with previous observations showing
the abundant expression of equilibrative nucleoside transporters on
vascular endothelium [10]. By contrast, the unchanged ATP and aden-
osine concentrations in Jurkat and EAhy926 cells after NBT treatment
suggest the contribution of other cellular mechanisms to nucleoside
homeostasis, most likely occurring via direct ectoenzymatic adeno-
sine deamination [13]. Noteworthy, harsh pipetting of the medium
directly down in three repetitions on the center of the wells with cul-
tured cells was accompanied by signiﬁcant (up to 4-fold) increases in
extracellular ATP, but not adenosine, levels (data not shown).
3.2. Comparative analysis of purine-converting activities by using radio-
TLC and novel enzyme-coupled sensing techniques
In the second study, cultured cells were incubated for 60 min at
37 °C with 2 μM ATP or adenosine followed by measurement of sub-
strate clearance and metabolite formation. Noteworthy, by replacing
KRPGmediumwith BSS in these particular assays we were able to de-
termine, along with nucleotides and nucleosides, the levels of yetFig. 4. Effect of pro-inﬂammatory stimuli on extracellular ATP and adenosine levels.
Cultures of HUVEC, EAhy926 (Eahy) and Jurkat T-lymphocytes were challenged for
1 h with the following agents: TNFα (200 U/ml), LPS (10 ng/ml), dibutyryl cAMP
(db-cAMP, 20 μg/ml), interleukin 1β (IL1β, 500 U/ml) and NBT (1 μM). Aliquots of
the medium were collected and assayed for ATP (A) and adenosine (B). The results
are presented as percentage of control purine concentrations measured in the absence
of treatment. *pb0.05 as compared with control untreated wells.another important product of ATP metabolism, PPi. Incubation of en-
dothelial and tumor cells with ATP caused its partial breakdown and
respective formation of dephosphorylated metabolites, ADP, AMP,
adenosine, inosine and hypoxanthine, as well as PPi (in case of
tumor cells PC3 andMDA-MB-231) (Fig. 5A–D; right panels). Further-
more, concurrent TLC analysis of time-courses of [3H]ATP metabolism
(Fig. 5A–D; left panels) allowed us to compare this novel sensing ap-
proach with “classical” TLC-based enzyme assay. For instance, rapid
clearance of exogenously applied ATP and its substantial conversion
into adenosine, inosine and hypoxanthine by HUVEC correlates well
with high ability of these cells to progressively hydrolyze [3H]ATP
into [3H]nucleosides through sequential ecto-nucleotidase reactions
(Fig. 5A). Incubation of Jurkat T-lymphocytes (Fig. 5B), PC3 (Fig. 5C)
and MDA-MB-231 (Fig. 5D) with ATP triggered its predominant con-
version into ADP without substantial increment in adenosine concen-
tration, as revealed by using both radio-TLC and newly developed
sensing techniques. The feasibility of this technique for assessment
of purine-converting pathways was further ascertained by using
3H-labeled or unlabeled adenosine as respective substrate. Fairly sim-
ilar results were obtained by using radio-TLC and ﬂuorometric
enzyme-coupled assays, with both approaches showing the high abil-
ity of Jurkat T-cells and, to a lesser degree, other cells to convert aden-
osine via inosine to hypoxanthine via sequential ecto-ADA and PNP
reactions (Fig. 6A–D).
3.3. Metastatic tumor, but not endothelial and lymphoid, cells display
ecto-NPP activity and constitutively maintain PPi in their vicinity
The revealed ability of PC3 and MDA-MB-231 cells to convert ATP
into AMP and PPi (see Fig. 5C,D) suggests the expression of NPP activ-
ities on these metastatic tumor cells. Additional analysis of basal PPi
levels further demonstrated that MDA-MB-231 and PC3 constitutively
maintain extracellular PPi at relatively high (>10 nM) and steady
state levels, which substantially exceed those measured in HUVEC
and Jurkat T-cells (Fig. 7A). For further substantiation of these results,
we performed autoradiographic TLC imaging of nucleotide-converting
pathways in these metastatic cells by using tracer [γ-32P]ATP. As
shown in Fig. 7B, incubation of PC3 cells with 10 μM [γ-32P]ATP caused
simultaneous generation of 32PPi and 32Pi (lane 1) and these catalytic
reactions were diminished in the presence of excessive amount
(100 μM) of unlabeled ATP (lane 2). Joint addition of [γ-32P]ATP and
UDP induced their transphosphorylation into [γ-32P]UTP and ADP
through NDPK reaction (lane 3). The presence of backward
ecto-adenylate kinase activity was ascertained by formation of [β-32P]
ADP during cell incubation with [γ-32P]ATP and AMP (lane 4) and inhi-
bition of this reaction by speciﬁc adenylate kinase inhibitor
diadenosine pentaphosphate (Ap5A; lane 5). Addition of [γ-32P]ATP
to another cell line, MDA-MB-231, also triggered its predominant
breakdown into AMP and 32PPi (lane 6). Strikingly, contrary to the
previously reported sole NTPDase1-medaited [γ-32P]ATP hydrolysis
into ADP and 32Pi by vascular endothelial [28,32] and lymphoid
[13,15] cells, the ability of PC3 and MDA-MB-231 cells to generate
both 32Pi and 32PPi indicates the co-expression of NTPDase and NPP ac-
tivities on these metastatic cells. Collectively, these ﬁndings conﬁrm
that appearance of PPi in the vicinity of tumor cells is coupled to ATP
release and its subsequent hydrolysis via NPP reaction. Direct measure-
ments also indicated that exogenous PPi was very poorly cleared by
these cells (data not shown), thus excluding the potential contribution
of tissue non-speciﬁc alkaline phosphatases to extracellular PPi
homeostasis.
3.4. Evaluation of extracellular purine homeostasis in human umbilical
cords
For testing whether the enzyme-coupled sensing techniques can
be employed for measurement of purine levels in the tissues, we
Fig. 5. Pattern of ATP metabolism by endothelial and tumor cells. Cultures of HUVEC (A), Jurkat T-lymphocytes (B), PC3 (C) and MDA-MB-231 (D) cells were incubated at 37 °C in
24-well-plate with exogenous ATP followed by measurement of the levels of ATP and related metabolites. Right panels show the concentrations of ATP, ADP, AMP, adenosine (Ado),
inosine (Ino), hypoxanthine (Hyp) and PPi in the conditioned medium collected after 60-minute incubation of the cells with 2 μM ATP and determined by using enzyme-coupled
bioluminescent and ﬂuorometric assays (mean±SEM; n=4–5). Cells were also incubated with 10 μM [3H]ATP and aliquots of the medium were periodically collected and ana-
lyzed by TLC for the amounts of [3H]ATP and its dephosphorylated metabolites. Left panels show the relative content of 3H-labeled ATP, ADP, AMP and nucleosides (comprising
the pooled adenosine, inosine and hypoxanthine fractions), expressed as percentage of initial concentrations. The graphs show mean data (n=2); the standard error of the
mean did not exceed the size of symbols.
1972 M. Helenius et al. / Biochimica et Biophysica Acta 1823 (2012) 1967–1975incubated freshly isolated human umbilical cords with 2 ml BSS for
20 min. The conditioned medium was shown to contain very high
concentrations of hypoxanthine (~3 μM) and nanomolar and
submicromolar levels of adenosine and inosine. Certain amounts of
PPi (~10 nM) were also detected in the medium, whereas ATP and
ADP were maintained at very low or undetectable levels (Fig. 8). Sur-
prisingly, incubation of umbilical cords with 2 μM ATP or adenosine
and subsequent analysis of the conditioned medium did not reveal
signiﬁcant shifts in the spectrum of measured metabolites (Fig. 8),
thus suggesting the ability of umbilical endothelial cells to maintain
nucleotide and nucleoside levels at certain levels via rapid turnover
of the released purinergic agonists.
4. Discussion
Release of ATP and other agonists represents a critical component
for initiating a purinergic signaling cascade. The novel ﬁndings of this
paper are that 1) a combination of enzyme-coupled bioluminescent
and ﬂuorometric assays has been designed and adapted for concurrent
measurement of the whole spectrum of adenine nucleotides, adenosine
and related compounds (inosine, hypoxanthine and PPi) within the
same sample; and 2) basal extracellular levels of ATP and otherphysiologically relevant agonists ADP, adenosine and PPi were shown
to be maintained at certain characteristic nanomolar levels by cultured
vascular endothelial, lymphoid and tumor cells and also in the intact tis-
sues. Furthermore, by quantifying the amounts of exogenously applied
purines and their metabolites, these sensing techniques may be
employed for evaluating purine-converting ectoenzymatic pathways.
Luciferin/luciferase method has long been known as the most sen-
sitive and selective approach for sensing ATP at various experimental
settings, including off-line nucleotide detection in sampled biological
ﬂuids and real-time luminometry using soluble or cell-surface at-
tached luciferase [4,5,16–18]. Moreover, the employment of particular
mixtures of enzymes and substrates allowed to apply bioluminescent
approach for simultaneous detection of ADP and ATP in pulmonary ar-
tery vasa vasorum endothelial cells [32], keratinocytes [35] and mu-
rine plasma [36,37], as well as extracellular ATP and PPi in vascular
smooth muscle cells [25,26]. Adenosine, inosine and/or hypoxanthine
levels can also be detected by employing speciﬁc mixture of enzymes
converting purines through the following sequence: adenosine →
inosine → hypoxanthine → uric acid + H2O2, followed by electro-
chemical [21,23,30], ﬂuorometric [38,39] or chemiluminescent [40]
detection of the generated H2O2. Currently, the enzyme-coupled ap-
proaches are widely employed for real time measurements of ATP-
Fig. 6. Pattern of adenosine metabolism by endothelial and tumor cells. HUVEC
(A), Jurkat T-lymphocytes (B), PC3 (C) and MDA-MB-231 (D) cells were incubated at
37 °C in 24-well-plate with adenosine. Right panels show the concentrations of aden-
osine (Ado), inosine (Ino) and hypoxanthine (Hyp) in the conditioned medium collect-
ed after 60-minute incubation of the cells with 2 μM adenosine and determined by
using enzyme-coupled ﬂuorometric assays (mean±SEM; n=4–5). Left panels show
time-courses of [3H]adenosine (10 μM) deamination by the cells and formation of
3H-labeled inosine and hypoxanthine, as determined by TLC (n=2).
1973M. Helenius et al. / Biochimica et Biophysica Acta 1823 (2012) 1967–1975and adenosine-releasing mechanisms by using microelectrode bio-
sensors coated with appropriate ATP- or nucleoside-metabolizing en-
zymes, respectively [21,22,31,41]. The alternative sensing assaysFig. 7. Extracellular nucleotide metabolism and pyrophosphate levels in cultured cells.
(A) The conditioned medium from cultured Jurkat, HUVEC, MDA-MB-231 (MDA) and
PC3 cells was collected after 60 (open bars) and 180 (closed bars) min and assayed
for PPi using enzyme-coupled bioluminescent technique (mean±SEM; n=5–8).
(B) PC3 and MDA-MB-231 (MDA) cells were incubated with 10 μM [γ-32P]ATP in the
absence (vehicle) or presence of 100 μM ATP, UDP, and AMP, as indicated. Some cells
were pretreated for 20 min with 50 μM Ap5A prior to addition of AMP and [γ-32P]
ATP. The blank shows the radiochemical purity of [γ-32P]ATP in the absence of cells. Ar-
rows indicate the positions of nucleotide standards, inorganic orthophosphate (Pi) and
pyrophosphate (PPi).include pharmacological cell-based approaches for detecting ATP
[42] and adenosine [43]; HPLC analysis of extracellular purines and
bases [12,44,45] or their ﬂuorescent 1,N6-ethenoadenine derivatives
[46,47]; continuous detection of ATP on living cells using atomic
force microscopy with myosin-functionalized scanning tips [48] or ty-
rosine kinase-modiﬁed silicon nanowire chips [49]; ﬂuorometric mi-
croscopic inspection of the cells loaded with ATP sensors luciferin or
quinacrine [15,20], as well as PPi detection by ﬂuorescent or colori-
metric chemosensors [50].
Despite the variety of sensing techniques, there is still a need for
simple and reliable assay for concurrent analysis of purine nucleotides
and nucleosides. By using a highly speciﬁc H2O2‐sensing reagent
Amplex Red, herewe developed a novel assay for detecting nanomolar
concentrations of AMP, adenosine, inosine and hypoxanthine. This
ﬂuorometric assay, when used in combination with other enzyme-
coupled bioluminescent techniques, provides a unique possibility of
quick and sensitive detection of ATP, ADP, AMP, adenosine and their
metabolites in aqueous homogenous solution without additional
manipulation, derivatization or dilution of sampled biological ﬂuids.
The results obtained are consistent with earlier observations showing
the release of ATP by different secretory and non-excitatory cells at
basal rates [4,5,11,14,47]. Furthermore, along with ATP, constitutive
presence of ADP and adenosine in endothelial, lymphoid and tumor
cells was demonstrated. Interestingly, among the studied cells, Jurkat
T-cells displayed the highest ATP:adenosine ratio (see Fig. 3D) and
these data corroborate previous observations that lymphoid and en-
dothelial cells generally display counteracting ATP-regenerating/
adenosine-deaminating and nucleotide-inactivating phenotypes, re-
spectively [13]. Previous estimates of ADP [35,36,45,47] and adeno-
sine [21,22,47] made in various cells, tissue slices and blood plasma
also reported purine levels from low nanomolar to submicromolar
range. It may be anticipated that maintenance of extracellular ADP
and subsequent desensitization of P2Y1 receptors predispose the de-
scribed earlier impaired platelet aggregation and P-selectin expres-
sion in response to exogenous ADP [36,45], and also diminished
antigen-presenting capacity and ADP-dependent death of epidermal
dendritic cells [35]. Likewise, persistent activation of the A2 receptors
by endogenous adenosine may lead to their partial desensitization in
various cell types and impaired cAMP responses to exogenously ap-
plied adenosine [32,47].
Unlikewell-characterized ATP release under various stimuli, cellular
mechanisms responsible for maintenance of ATP and other purines at
basal levels remain largely unknown. One interesting hypothesis is
that basal nanomolar extracellular ATP level basically reﬂects a minor
fraction (so-called “purinergic tone” [11]) of the actual mass of micro-
molar pericellular nucleotide pool, which is localized in the immediate
cell vicinity and exchangedwith bulk phase via dissociation–association
mechanisms [4,15–17]. Given that apparent Km values for purinergic
ectoenzymes liewithinmicromolar range [9,28], we also do not exclude
that low nanomolar concentrations of extracellular purines are below
the threshold level required for their efﬁcient binding to the
substrate-binding active centers of the enzymes. It may particularly
explainwhybaseline levels of ATP and other purines remained essential-
ly constant throughout the 3-hour incubation period, even despite the
presence of high ecto-nucleotidase and ADA activities on the cells stud-
ied (see Figs. 6 and 7; also [13]). At the same time, induction of additional
release of ATP by different mechanical or chemical stimuli would
strongly accelerate the catalytic rates of purinergic enzymes and rapidly
restore extracellular ATP and its metabolites to basal steady-state levels,
thereby preventing excessive activation and/or desensitization of
purinergic receptors. Indeed, except for signiﬁcant LPS-mediated in-
crease in adenosine, application of other pro-inﬂammatory agents did
not affect extracellular levels of ATP and adenosine (see Fig. 4).
Besides in vitro analysis of cell cultures, these sensing techniques
can also be applied for detecting purine levels in the tissues, as
ascertained by ex vivo experiments with human umbilical cords
Fig. 8. Ex vivo analysis of purine nucleotides, nucleosides and PPi in human umbilical cords. The concentrations of ATP, ADP, PPi, adenosine, inosine and hypoxanthine were deter-
mined in the conditioned “intracordial” ﬂuid obtained after 20-minute incubation of fresh umbilical cords with BSS medium, either alone (basal) or supplemented with 2 μM ATP or
adenosine (mean±SEM; n=3–5).
1974 M. Helenius et al. / Biochimica et Biophysica Acta 1823 (2012) 1967–1975(see Fig. 8). Assuming that endothelial lining primarily contributes to
the measured “intracordial” homeostasis, the obtained data on
undetectable ATP/ADP and high nanomolar adenosine/inosine levels
correlate well with data on predominant nucleotide inactivating/
adenosine generating phenotype in cultured HUVEC and other vascu-
lar endothelial cells (see Fig. 5A; also [12,13]), and are basically con-
sistent with current view of important role of adenosine in the
maintenance of endothelial barrier function [10,32,46]. As for the re-
vealed ability of umbilical cords to maintain nanomolar PPi and mi-
cromolar hypoxanthine levels (see Fig. 8), it presumably reﬂects the
existence of pyrophosphate [24] and hypoxanthine [34,44] “pools”
freely circulating in human blood and other extracellular ﬂuids.
Another important application of these sensing assays may in-
clude the assessment of ectoenzymatic purine-converting pathways
(see Figs. 6 and 7), thus providing potential alternative to TLC assays,
which are widely employed for measurement of purinergic activities
in various cells and tissues [13,37,51]. Strikingly, contrary to TLC anal-
ysis of the conversion of radiolabelled substrates, current measure-
ments quantify a bulk pool of both exogenously applied and
endogenously released purines and their metabolites. Moreover, by
using these sensing assays we revealed the ability of metastatic pros-
tate carcinoma cells PC3 and breast cancer cells MDA-MB-231 to
maintain nanomolar levels of PPi, which primarily derives from en-
dogenous ATP in the course of NPP reaction. Current models consider
extracellular ATP as a potent tumorigenic agent triggering diverse
tumor-promoting or ‐suppressive (depending on the tumor type) re-
sponses via direct activation of P2 receptors and/or subsequent nucle-
otide breakdown into adenosine [2,51,52]. So far, extracellular
ATP-PPi axis has been rather neglected as a potential mechanism
regulating migration and invasion of metastatic cancer cells. Interest-
ingly, a broadly employed class of synthetic analogues of PPi,
bisphosphonates, has been widely used for preventing bone resorp-
tion and osteoporosis, as well as for treatment of malignancies associ-
ated with bone metastasis, including breast and prostate cancers
[24,53,54]. Most of these therapeutic effects are thought to be mediat-
ed through the inhibition of mevalonate/cholesterol biosynthesis or
interference with other ATP-dependent intracellular pathways.
Given that some bisphosphonates (speciﬁcally, non-nitrogen con-
taining clodronate and etidronate) can substitute for PPi by metabolic
incorporation into non-hydrolyzable ATP analogues [54], it would be
attractive to hypothesize that anti-tumor effects of these drugs are
deﬁned, at least in part, by interference with the function of the
enzymes involved in extracellular PPi homeostasis.
In summary, the results obtained imply a complex pattern of nu-
cleotide turnover where different endothelial, lymphoid and tumor
cells constitutively maintain ATP, ADP and adenosine at characteristic
steady-state levels via counterbalanced release and inactivation of
endogenous ATP and other purines. Furthermore, here we provide a
novel insight into the mechanisms underlying tumorigenic effects of
ATP by demonstrating the ability of metastatic breast and prostate
cancer cell lines to maintain PPi, which primarily derives from
extracellular ATP in the course of NPP reaction. Simultaneous mea-
surement of ATP, ADP, AMP, adenosine, inosine and PPi within lownanomolar ranges may provide an extremely useful tool for further
understanding the signal transduction pathways coordinately trig-
gered by these agonists at different (patho)physiological states.
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